Search the Newsreel

Renaissance Technologies LLC Trims Stock Holdings in LifeMD, Inc. $LFMD

Renaissance Technologies LLC reduced its stake in LifeMD, Inc. by 25.4% in the first quarter, selling 380,000 shares and retaining over 1.1 million shares. Despite this, analysts generally hold a "Moderate Buy" consensus for LifeMD, with an average price target of $7.57, though some …

LifeMD (NASDAQ:LFMD) Price Target Lowered to $9.00 at HC Wainwright

HC Wainwright has lowered its price target for LifeMD (NASDAQ:LFMD) to $9.00 from $10.00 but maintained a "buy" rating, indicating a potential upside of 164.71%. The revision follows LifeMD's recent quarterly results, which missed analyst expectations with a reported loss of $0.16 per share …

LifeMD, Inc. Stock 12‑Month Price Target Cut to $9, Implies 145% Upside

LifeMD, Inc.'s average 12-month price target has been reduced from $9.88 to $9 by 8 analysts, with forecasts ranging from $7 to $15 per share. Despite the cut, this new target still suggests a substantial 145% potential upside from its Aug. 5 closing price. …

LifeMD Inc reports results for the quarter ended June 30 - Earnings Summary

LifeMD Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief announcement of these financial results. To access the full details, readers are directed to the complete article available on TradingView.

LifeMD, Inc. Q2 2026: Revenue $47.28M, EPS $(0.16) — 10-Q Summary

LifeMD, Inc. reported its second-quarter 2026 results, showing a revenue of $47.28 million, a 3.6% decrease year-over-year, and a net loss of $7.86 million, significantly wider than the previous year's loss. The diluted loss per share was $(0.16). Despite a decline in online product …

(LFMDP) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis of LifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP), noting a neutral sentiment and a wait-and-see approach. It highlights an exceptional 12.0:1 risk-reward setup targeting a 3.6% gain, with specific trading strategies for position trading, …

LifeMD Reports Second Quarter 2026 Results, Reaches Branded GLP-1 Transition Milestone and Raises Full-Year Guidance

LifeMD, Inc. announced its Q2 2026 financial results, reporting revenues of $47.3 million and a sequential improvement in adjusted EBITDA loss to $3.5 million. The company is transitioning its weight management program to branded GLP-1 therapies, which now account for 95% of new patients, …

LifeMD (NASDAQ:LFMD) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

LifeMD (NASDAQ:LFMD) reported its quarterly earnings, missing analyst expectations with an adjusted EPS of negative $0.16 against a consensus of negative $0.15, and revenue of $47.28 million, falling short of the $49.16 million estimate. The telehealth company also reduced its full-year 2026 guidance due …

LifeMD (NASDAQ:LFMD) Shares Slide After Q2 Revenue and EPS Miss

LifeMD (NASDAQ:LFMD) reported disappointing Q2 2026 results, missing both revenue and non-GAAP EPS consensus estimates. The virtual care and pharmacy services company posted revenue of $47.3 million against a $50.1 million consensus, and a non-GAAP loss per share of $0.16 compared to an expected …

LifeMD (NASDAQ: LFMD) posts Q2 $47.3M revenue, cuts 2026 guidance

LifeMD reported Q2 2026 telehealth revenue of $47.3 million, a 4% year-over-year decrease, though within guidance, as it transitions weight-management patients to branded GLP-1 therapies and longer subscriptions. The company increased active subscribers by 20% to approximately 356,000, and gross margin expanded to 89%. …

LifeMD earnings missed by $0.06, revenue fell short of estimates

LifeMD Q2 Results: Revenue falls 3%, adjusted EBITDA loss widens

LifeMD reported a 3% year-over-year revenue decline to $47.3 million in Q2 2026, while its adjusted EBITDA swung to a $3.5 million loss, primarily due to higher customer acquisition costs and a strategic shift to branded GLP-1 therapies. Despite the revenue dip, gross margin …

Earnings call transcript: LifeMD posts Q2 revenue miss, shares sink in after-hours

LifeMD (LFMD) reported a Q2 revenue miss of $47.3 million against an analyst forecast of $49.15 million, alongside an adjusted EBITDA loss and a lowered full-year 2026 outlook, causing shares to drop over 17% in after-hours trading. Despite the financial setbacks, the company highlighted …

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD, Inc. (LFMD) reported a Q2 loss of $0.16 per share, which was an earnings surprise of +20.00% compared to the Zacks Consensus Estimate of a $0.2 loss. However, the company missed revenue estimates, posting $47.28 million against an estimated $49.10 million. Despite outperforming …

LifeMD Q2 2026 slides tout AI platform, results miss targets

LifeMD presented an investor overview in August 2026, highlighting its AI-enabled virtual care platform and growth strategy, despite second-quarter results missing Wall Street expectations. The company's shares fell significantly following the earnings release, nearing its 52-week low. The presentation emphasized LifeMD's transformation into a …

LifeMD (NASDAQ: LFMD) posts $15.96M loss but holds $25.1M cash and $30M credit line

LifeMD, Inc. reported a Q2 2026 net loss of $15.96 million from continuing operations, despite revenues of $47.3 million, a slight decrease from the prior year. The company maintains a strong liquidity position with $25.1 million in cash, no outstanding debt, and an undrawn …

LifeMD (LFMD) Earnings Date and Reports 2026

Earnings To Watch: LifeMD Inc (LFMD) Q2 2026 -- GF Value Sees 92% Upside

LifeMD Inc expected to post a loss of 15 cents a share - Earnings Preview

LifeMD Inc is projected to report a loss of 15 cents per share, according to this earnings preview. The article indicates that this financial expectation comes from Refinitiv. Full details are available to TradingView subscribers.

LifeMD Inc (LFMD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of LifeMD Inc (LFMD), noting its current valuation score of 9.86 and its rank within the Healthcare Equipment & Supplies industry. It details the company's current P/E ratio, comparing it to recent highs and lows. The article also …

LifeMD (LFMD) Projected to Announce Quarterly Earnings on Wednesday

LifeMD Inc (LFMD) Institutional Confidence

LifeMD Inc (LFMD) currently has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 42.85%, showing a slight quarter-over-quarter decrease of 0.30%. The largest institutional shareholder is Bill Nygren …

LifeMD Inc (LFMD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of LifeMD Inc (LFMD), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholders by type and provides a historical overview of institutional shareholding, including the number of institutions, shares held, …

LifeMD Inc (LFMD) Income Statement

This article provides the quarterly and annual income statements for LifeMD Inc (LFMD), offering detailed financial data on revenues, expenses, and net income over a prolonged period. It includes year-over-year percentage changes for various financial metrics, helping investors assess the company's performance and operational …

LFMD|LifeMD Inc|Price:3.710|Chg%:-0.160

LifeMD Inc. (LFMD) is a virtual healthcare and pharmacy service provider with strong fundamentals and high growth potential, though its stock performance has been weak recently. The company's valuation is considered fairly valued within its industry, and it has a high institutional ownership. Analysts …

LifeMD schedules Aug. 5 update after U.S. markets close

LifeMD (Nasdaq: LFMD) is scheduled to report its second-quarter and first-half 2026 financial results on August 5, 2026, after the U.S. market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss these results. Historical data shows that prior …

LifeMD to Report Second Quarter 2026 Financial Results on August 5

LifeMD, Inc. (Nasdaq: LFMD) announced it will release its financial results for the second quarter and six months ended June 30, 2026, after the U.S. financial markets close on August 5, 2026. The company will also host a conference call on the same day …

Lifemd, Inc. (LFMD) Q4 2023 Earnings Report - Results, Call & Slides

LifeMD (LFMD) announced its Q4 2023 earnings, reporting an actual EPS of -$0.12, beating the consensus of -$0.14 by $0.02. The company also surpassed revenue expectations, with actual revenue of $44.86M against an expected $41.30M, representing a 59.53% year-over-year growth. The earnings call was …

Earnings call transcript: LifeMD Q1 2026 beats EPS and revenue forecasts

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

After the bell May 6: LifeMD sets Q1 results call for 4:30 p.m. ET

How The LifeMD (LFMD) Story Is Shifting Around GLP-1 Growth Plans And 2026 Expectations

LifeMD Q4 Earnings Call Highlights